2 août 2024 – At the end of July 2024, Swissmedic granted authorization for the dengue fever vaccine Qdenga, manufactured by Takeda Pharma AG, for distribution in the Swiss market. This marks the first approval of a dengue vaccine in Switzerland. Qdenga is authorized for use in individuals aged 4 and older who are traveling to regions where dengue is prevalent, including subtropical and tropical areas in Central Africa, Latin America, India, Southeast Asia, and southern parts of the USA (Texas). The vaccine comprises attenuated (weakened) strains of dengue virus types 1, 2, 3, and 4, which stimulate the immune system to generate antibodies without causing the disease. Dengue fever, spread by infected mosquitoes, typically manifests symptoms such as fever, headache, muscle pain, and rash between four and seven days post-infection.

For more information, see here.